← Eichor
Condition: Ocular Myasthenia Gravis Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Ocular Myasthenia Gravis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
Phase 1/Phase 2 · 1 location(s) · Tianjin Medical University General Hospital · NCT07022197Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Phase N/A · 7 location(s) · Alexion Pharmaceuticals, Inc. · NCT06312644Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in
EARLY_Phase 1 · 1 location(s) · Tianjin Huanhu Hospital · NCT06939166Capturing Key MG-symptoms Using Smartphone Recordings.
Phase N/A · 2 location(s) · Leiden University Medical Center · NCT06743490Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis
Phase N/A · 1 location(s) · Huashan Hospital · NCT07146425TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
Phase N/A · 1 location(s) · Tang-Du Hospital · NCT04182984Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous Sys
EARLY_Phase 1 · 1 location(s) · Tongji Hospital · NCT04561557Analysis of the Role of AIRE in Autoimmune Neurological Diseases Associated With Autoantibodies
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06941584Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Media
Phase 1 · 1 location(s) · Tongji Hospital · NCT07526493A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
Phase 3 · 1 location(s) · RemeGen Co., Ltd. · NCT07249632Biomarkers in Autoimmune Disease of Nervous System
Phase N/A · 1 location(s) · Tongji Hospital · NCT06502015Cohort Study on Neuroimmune Diseases in the Reproductive Age
Phase N/A · 1 location(s) · Third Affiliated Hospital, Sun Yat-Sen University · NCT07653984Predictors and Prognostic Factors of Myasthenia Gravis Outcome
Phase N/A · 1 location(s) · Assiut University · NCT05214612A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Phase 1 · 8 location(s) · TG Therapeutics, Inc. · NCT06680037A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Phase 1 · 1 location(s) · RenJi Hospital · NCT06249438A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
Phase 1/Phase 2 · 25 location(s) · ImmunAbs Inc. · NCT07250750Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Phase 1 · 1 location(s) · Polina Stepensky · NCT07085676Myasthenia Gravis Foundation of America Global MG Patient Registry
Phase N/A · 1 location(s) · Myasthenia Gravis Foundation of America · NCT06617741Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
NA · 1 location(s) · Centre Hospitalier Universitaire de Liege · NCT07136844Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-
Phase 3 · 11 location(s) · Fondation Ophtalmologique Adolphe de Rothschild · NCT06342544The Effectiveness of Bu Zhong Yi Qi Tang in Patients with Myasthenia Gravis
NA · 1 location(s) · Cheng, yu-ting · NCT06881173A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Phase 3 · 2 location(s) · UCB Biopharma SRL · NCT07463521
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.